The Time is Right to Invest in Canadian Biotechnology and Stop Subsidizing Foreign Biotechnology Companies

Canada has been at the forefront of medical breakthroughs, yet foreign companies continue to capitalize on our innovations. It’s time to change the narrative. Investing in Canadian biotechnology means fostering innovation, strengthening our economy, and ensuring that life-changing advancements benefit Canadians first.  

This op-ed by P.J. Devereaux, CEO and Scientific Director, World Health Research Trust; Dr. Maura Campbell, President and CEO, OBIO®; and David Conen, Senior Scientist, Population Health Research Institute highlights the urgent need for clinical trial investment, tax incentives, and stronger industry collaboration to keep Canadian biotech thriving. Let’s champion homegrown talent and build a globally competitive biotech sector.